Lipid metabolism as a target for cancer drug resistance: progress and prospects

被引:16
|
作者
Wang, Zi'an [1 ,2 ]
Wang, Yueqin [1 ,2 ]
Li, Zeyun [1 ,2 ]
Xue, Wenhua [1 ,2 ]
Hu, Shousen [3 ]
Kong, Xiangzhen [1 ,2 ]
机构
[1] Zhengzhou Univ, Affiliated Hosp 1, Dept Pharm, Zhengzhou, Peoples R China
[2] Zhengzhou Univ, Henan Key Lab Precis Clin Pharm, Zhengzhou, Peoples R China
[3] Zhengzhou Univ, Affiliated Hosp 1, Dept Otolaryngol Head & Neck Surg, Zhengzhou, Peoples R China
基金
中国国家自然科学基金;
关键词
drug resistance; lipid metabolism; combination drug; inhibitor; chemotherapy resistance; targeted therapy; FATTY-ACID SYNTHASE; STEAROYL-COA DESATURASE; ERBB-2 ONCOGENE OVEREXPRESSION; BREAST-CANCER; THERAPEUTIC TARGET; IN-VIVO; CHOLESTEROL; CELLS; CHEMOTHERAPY; EXPRESSION;
D O I
10.3389/fphar.2023.1274335
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Cancer is the world's leading cause of human death today, and the treatment process of cancer is highly complex. Chemotherapy and targeted therapy are commonly used in cancer treatment, and the emergence of drug resistance is a significant problem in cancer treatment. Therefore, the mechanism of drug resistance during cancer treatment has become a hot issue in current research. A series of studies have found that lipid metabolism is closely related to cancer drug resistance. This paper details the changes of lipid metabolism in drug resistance and how lipid metabolism affects drug resistance. More importantly, most studies have reported that combination therapy may lead to changes in lipid-related metabolic pathways, which may reverse the development of cancer drug resistance and enhance or rescue the sensitivity to therapeutic drugs. This paper summarizes the progress of drug design targeting lipid metabolism in improving drug resistance, and providing new ideas and strategies for future tumor treatment. Therefore, this paper reviews the issues of combining medications with lipid metabolism and drug resistance.
引用
收藏
页数:12
相关论文
共 50 条
  • [21] Are we Missing the Target? - Cancer Stem Cells and Drug Resistance in Non-small Cell Lung Cancer
    Gottschling, Sandra
    Schnabel, Philipp A.
    Herth, Felix J. F.
    Herpel, Esther
    CANCER GENOMICS & PROTEOMICS, 2012, 9 (05) : 275 - 286
  • [22] Lipid metabolism in cancer
    Santos, Claudio R.
    Schulze, Almut
    FEBS JOURNAL, 2012, 279 (15) : 2610 - 2623
  • [23] Lipid metabolism and cancer progression: The missing target in metastatic cancer treatment
    Omabe, Maxwell
    Ezeani, Martin
    Omabe, Kenneth Nwobini
    JOURNAL OF APPLIED BIOMEDICINE, 2015, 13 (01) : 47 - 59
  • [24] Unraveling lipid metabolism reprogramming for overcoming drug resistance in melanoma
    Wang, Ruilong
    Yan, Qin
    Liu, Xiao
    Wu, Jinfeng
    BIOCHEMICAL PHARMACOLOGY, 2024, 223
  • [25] MiRNAs: main players of cancer drug resistance target ABC transporters
    Mohammadi, Forogh
    Nejatollahi, Masoumeh
    Sheikhnia, Farhad
    Ebrahimi, Yaser
    Mohammadi, Mahya
    Rashidi, Vahid
    Alizadeh-Fanalou, Shahin
    Azizzadeh, Bita
    Majidinia, Maryam
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2025, : 6239 - 6291
  • [26] Lipid metabolism in cancer progression and therapeutic strategies
    Fu, Yan
    Zou, Tiantian
    Shen, Xiaotian
    Nelson, Peter J.
    Li, Jiahui
    Wu, Chao
    Yang, Jimeng
    Zheng, Yan
    Bruns, Christiane
    Zhao, Yue
    Qin, Lunxiu
    Dong, Qiongzhu
    MEDCOMM, 2021, 2 (01): : 27 - 59
  • [27] Tumor glycolysis as a target for cancer therapy: progress and prospects
    Shanmugasundaram Ganapathy-Kanniappan
    Jean-Francois H Geschwind
    Molecular Cancer, 12
  • [28] Tumor glycolysis as a target for cancer therapy: progress and prospects
    Ganapathy-Kanniappan, Shanmugasundaram
    Geschwind, Jean-Francois H.
    MOLECULAR CANCER, 2013, 12
  • [29] circRNAs in drug resistance of breast cancer
    Misir, Sema
    Yaman, Serap Ozer
    Petrovic, Nina
    Sumer, Ceren
    Hepokur, Ceylan
    Aliyazicioglu, Yuksel
    ONCOLOGY RESEARCH, 2022, 30 (04) : 157 - 172
  • [30] Nanomedicines for Overcoming Cancer Drug Resistance
    Hu, Tingting
    Gong, Hanlin
    Xu, Jiayue
    Huang, Yuan
    Wu, Fengbo
    He, Zhiyao
    PHARMACEUTICS, 2022, 14 (08)